Matchpoint Therapeutics Announces $150 Million Series B Financing to Advance Pipeline of First-In-Class Oral Small Molecules for Autoimmune and Inflammatory Diseases

Financing co-led by Nextech Invest and Norwest, with participation from new and existing investors Proceeds to support clinical development of MPT-062, an oral first-in-class T cell modulator, to begin in… The post Matchpoint Therapeutics Announces $150 Million Series B Financing to Advance Pipeline of First-In-Class Oral Small Molecules for Autoimmune and Inflammatory Diseases appeared first on Matchpoint Therapeutics .